ストックスクリーナーアプリを入手
7.33
2.14%
-0.16
前日終値:
$7.49
開ける：
$7.41
24時間の取引高:
1.27M
Relative Volume:
0.67
時価総額：
$1.16B
収益：
$177.28M
当期純損益:
$-195.24M
株価収益率:
-5.4701
EPS:
-1.34
ネットキャッシュフロー:
$-114.54M
1週間 パフォーマンス:
-5.11%
1か月 パフォーマンス:
-2.79%
6か月 パフォーマンス:
+57.97%
1年 パフォーマンス:
+200.41%
1日の値動き範囲:
$7.25
$7.55
1週間の範囲:
$7.25
$8.295
52週間の値動き範囲:
$2.28
$9.01
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
名前
Adaptive Biotechnologies Corp
セクター
電話
206-659-0067
住所
1165 EASTLAKE AVE E, SEATTLE, WA
ADPT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
7.33 | 1.16B | 177.28M | -195.24M | -114.54M | -1.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-21 | アップグレード | Goldman | Neutral → Buy |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-12-21 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | 開始されました | Credit Suisse | Underperform |
| 2022-06-03 | 開始されました | Piper Sandler | Neutral |
| 2022-02-16 | 繰り返されました | BTIG Research | Buy |
| 2022-02-16 | 繰り返されました | BofA Securities | Buy |
| 2022-02-16 | 繰り返されました | Goldman | Neutral |
| 2022-02-16 | 繰り返されました | JP Morgan | Overweight |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-03-03 | ダウングレード | Goldman | Buy → Neutral |
| 2020-10-08 | 再開されました | BTIG Research | Buy |
| 2020-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-06-03 | 開始されました | Goldman | Buy |
| 2019-07-23 | 開始されました | BTIG Research | Buy |
| 2019-07-22 | 開始されました | BofA/Merrill | Buy |
| 2019-07-22 | 開始されました | Cowen | Outperform |
| 2019-07-22 | 開始されました | Goldman | Neutral |
| 2019-07-22 | 開始されました | Guggenheim | Buy |
| 2019-07-22 | 開始されました | William Blair | Outperform |
すべてを表示
Adaptive Biotechnologies Corp (ADPT) 最新ニュース
Franklin Resources Inc. Invests $443,000 in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025 | ADPT Stock News - GuruFocus
Corebridge Financial Inc. Has $345,000 Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025 - The Manila Times
25,800 Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Acquired by KLP Kapitalforvaltning AS - Defense World
Adaptive Biotechnologies' Mantle Cell Lymphoma Test Receives Expanded Medicare Coverage - MarketScreener
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma - The Manila Times
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Guess, Tesla, Nvidia And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Swiss National Bank Takes $1.22 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Proficio Capital Partners LLC Takes Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Corp: Analyzing ADPT Stock Trends - investchronicle.com
Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 12-Month HighShould You Buy? - MarketBeat
Adaptive Biotechnologies’ chief scientific officer sells shares for $15,282 By Investing.com - Investing.com Australia
Adaptive Biotechnologies’ chief scientific officer sells shares for $15,282 - Investing.com India
Charles Schwab Investment Management Inc. Acquires 39,831 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies stock hits 52-week high at $8.95 By Investing.com - Investing.com Australia
Adaptive Biotechnologies stock hits 52-week high at $8.95 - Investing.com
Amundi Boosts Stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up – What’s Next? - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Rating Upgraded by The Goldman Sachs Group - Defense World
Bank of New York Mellon Corp Has $2.18 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Gains Following Goldman Sachs Upgrade, Share Climb 6% Near Friday Close - MarketScreener
Analyst Expectations For Adaptive Biotechnologies's Future - Benzinga
Scholastic Posts Strong Earnings, Joins Ouster, Torrid Holdings, Adaptive Biotechnologies And Other Big Stocks Moving Higher On Friday - Benzinga
Goldman Sachs Upgrades Adaptive Biotechnologies to Buy From Neutral, Adjusts Price Target to $9 From $8 - Marketscreener.com
Goldman Sachs lifts Adeptus Biotech stock rating to Buy, target to $9 - Investing.com
Adaptive Biotechnologies (ADPT): Among Stocks Insiders Are Selling In March - Insider Monkey
10 Stocks Insiders Are Selling In March - Insider Monkey
Proficio Capital Partners LLC Takes $93,000 Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Critical Survey: Adaptive Biotechnologies (NASDAQ:ADPT) vs. Beam Therapeutics (NASDAQ:BEAM) - Defense World
Adaptive Biotechnologies director sells shares worth $70,500 By Investing.com - Investing.com Canada
Adaptive Biotechnologies director sells shares worth $70,500 - Investing.com India
Adaptive Biotechnologies director sells shares worth $402,270 - Investing.com
Adaptive Biotechnologies Executives Sell Shares - TradingView
Minimal Residual Disease Market Expected to rise, 2032 | Adaptive Biotechnologies, Bristol-Myers Squibb Company, Natera, Kite Pharma, Amgen Inc., expected to boost the market - Barchart
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma - The Manila Times
US Bancorp DE Sells 43,819 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Revolutionary 7x Sensitivity Boost: Adaptive's New Cancer Detection Test Transforms Lymphoma Monitoring - Stock Titan
Insider Selling: Adaptive Biotechnologies Co. (NASDAQ:ADPT) CEO Sells $819,109.98 in Stock - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.5% on Insider Selling - Defense World
Adaptive Biotechnologies director sells $124,372 in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies CEO Chad Robins sells $1.6 million in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies’ chief commercial officer Sharon Benzeno sells $311,792 in stock By Investing.com - Investing.com South Africa
Principal Financial Group Inc. Purchases Shares of 143,444 Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies president Julie Rubinstein sells $415,539 in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies CFO sells shares worth $72,072 By Investing.com - Investing.com South Africa
Adaptive Biotechnologies’ chief scientific officer sells $675k in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies chief people officer sells $145,845 in stock - Investing.com
Adaptive Biotechnologies Corp (ADPT) 財務データ
収益
当期純利益
現金流量
EPS
2.51%
大文字化:
|
ボリューム (24 時間):